P. Doshi

发表

Transparency interrupted: the curtailment of the European Medicines Agency's Policy on access to documents.

P. Doshi, 2013, JAMA internal medicine.

Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports

Tom Jefferson, Peter Doshi, T. Jefferson, 2013, BMJ Open.

Restoring invisible and abandoned trials: a call for people to publish the findings

S. Vedula, K. Dickersin, T. Jefferson, 2013, The BMJ.

The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience

Tom Jefferson, Peter Doshi, Chris Del Mar, 2012, PLoS medicine.

FDA to begin releasing clinical study reports in pilot programme

P. Doshi, 2018, British Medical Journal.

The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer.

T. Jefferson, P. Doshi, 2013, JAMA internal medicine.

For peer review only Clinical Study Reports of randomized controlled trials - an exploratory review of previously confidential industry reports

P. Doshi, 2012 .

Raw data from clinical trials: within reach?

S. Goodman, J. Ioannidis, P. Doshi, 2013, Trends in pharmacological sciences.

Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy.

Lorenzo Bertizzolo, Tianjing Li, Kay Dickersin, 2017, Journal of clinical epidemiology.

Ramifications of adverse events in children in Australia

P. Collignon, T. Jefferson, P. Doshi, 2010, BMJ : British Medical Journal.

Disclose Data Publicly, without Restriction

T. Jefferson, P. Doshi, 2017, Journal of Law, Medicine & Ethics.

Putting GlaxoSmithKline to the test over paroxetine

P. Doshi, 2013, BMJ.

Influenza vaccines: time for a rethink.

P. Doshi, 2013, JAMA internal medicine.

Influenza: marketing vaccine by marketing disease

P. Doshi, 2013, BMJ.

INFLUENZA Influenza : marketing vaccine by marketing disease

P. Doshi, 2013 .

The 2009 influenza pandemic.

Peter Doshi, P. Doshi, 2013, The Lancet. Infectious diseases.

Authors’ reply to Dunning

T. Jefferson, P. Doshi, 2014, BMJ : British Medical Journal.

Trends in recorded influenza mortality: United States, 1900-2004.

P. Doshi, 2008, American journal of public health.

FDA unease about faster drug approval

P. Doshi, 2017, British Medical Journal.

Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events.

E. Mayo-Wilson, S. Vedula, K. Dickersin, 2019, Journal of clinical epidemiology.

Speeding new antibiotics to market: a fake fix?

P. Doshi, 2015, BMJ : British Medical Journal.

FDA drug summaries: a simplification too far?

P. Doshi, 2015, BMJ : British Medical Journal.

US incentive scheme for neglected diseases: a good idea gone wrong?

P. Doshi, 2014, BMJ : British Medical Journal.

WHO’s malaria vaccine study represents a “serious breach of international ethical standards”

P. Doshi, 2020, BMJ.

Integrated Drug Reviews at the US Food and Drug Administration-Legal Concerns and Knowledge Lost.

P. Doshi, M. Herder, Christopher J. Morten, 2020, JAMA internal medicine.

The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us?

P. Doshi, Anna Hung, J. Sieluk, 2019, Journal of the American Pharmacists Association : JAPhA.

The Untapped Potential of Pharmacy Leaflets for Informing Patients About Drug Benefits and Risks.

P. Doshi, Anna Hung, J. Sieluk, 2016, JAMA internal medicine.

North American regulatory agencies can and should make clinical trial data publicly available

P. Doshi, N. Persaud, 2016, Canadian Medical Association Journal.

Pandemic influenza: severity must be taken into account.

P. Doshi, 2010, The Journal of infectious diseases.

Ensuring safe and effective drugs: who can do what it takes?

Matthew J. Thompson, C. Heneghan, T. Jefferson, 2011, BMJ : British Medical Journal.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children

T. Jefferson, C. Del Mar, P. Doshi, 2010, The Cochrane database of systematic reviews.

Statins for primary prevention: what is the regulator’s role?

T. Jefferson, P. Doshi, M. Demasi, 2020, BMJ Evidence-Based Medicine.

Reason for optimism

P. Doshi, 2008, BMJ : British Medical Journal.

Estimation of death rates from pandemic influenza

P. Doshi, 2007, The Lancet.

The wider role of regulatory scientists

F. Godlee, P. Doshi, 2017, British Medical Journal.

Restoring biomedical literature with RIAT

L. Shamseer, T. Jefferson, P. Doshi, 2018, British Medical Journal.

Evaluation of Publicly Available Information on Sex-Related Differences in the Efficacy and Safety of Newly Approved Medications

P. Doshi, H. Hassan, Kyungwan Hong, 2022, Journal of General Internal Medicine.

Possible harms of oseltamivir—a call for urgent action

C. Mar, Mark Jones, T. Jefferson, 2009, The Lancet.

EFPIA-PhRMA’s principles for clinical trial data sharing have been misunderstood

P. Doshi, 2013, BMJ.

Covid-19: Should doctors recommend treatments and vaccines when full data are not publicly available?

P. Doshi, D. Healy, Raymond M. Johnson, 2020, BMJ.

Challenges of independent assessment of potential harms of HPV vaccines

P. Gøtzsche, T. Jefferson, P. Doshi, 2018, British Medical Journal.

Time for a rethink

P. Doshi, 2009, Veterinary Record.

Antivirals for Treatment of Influenza

C. Heneghan, T. Jefferson, P. Doshi, 2012, Annals of Internal Medicine.

Word limits best explain failings of industry supported meta-analyses

C. Viboud, P. Doshi, Black Wc, 2006 .

Safety and efficacy of inactivated influenza vaccines in children.

C. Del Mar, P. Collignon, T. Jefferson, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Digging for data on harms in duloxetine trials

P. Doshi, S. dosReis, J. Zito, 2014, BMJ : British Medical Journal.

Does oseltamivir really reduce complications of influenza?

Matthew J. Thompson, C. Heneghan, C. Mar, 2011, Clinical Infectious Diseases.

Rethinking credible evidence synthesis

T. Jefferson, P. Doshi, Mark Jones, 2012, BMJ : British Medical Journal.

Neuropsychiatric Adverse Events and Oseltamivir for Prophylaxis

Mark Jones, T. Jefferson, P. Doshi, 2012, Drug Safety.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children

C. Del Mar, Matthew J. Thompson, C. Heneghan, 2014, Sao Paulo medical journal = Revista paulista de medicina.

EMA scales back transparency initiatives because of workload

P. Doshi, 2018, British Medical Journal.

Neuraminidase Inhibitors and Influenza Infection.

T. Jefferson, P. Doshi, 2016, JAMA internal medicine.

Neuraminidase inhibitors for influenza complications

C. Heneghan, C. Mar, J. Howick, 2014, The Lancet.

Clinical trial data: get them while you can

T. Groves, P. Doshi, E. Loder, 2014, BMJ : British Medical Journal.

Popular and Scientific Attitudes Regarding Pandemic Influenza

P. Doshi, 2008, Emerging infectious diseases.

Pandemrix vaccine: why was the public not told of early warning signs?

P. Doshi, 2018, British Medical Journal.

Japanese Childhood Vaccination Policy

P. Doshi, A. Akabayashi, 2010, Cambridge Quarterly of Healthcare Ethics.

The importance of influenza vaccination-reply.

P. Doshi, 2014, JAMA Internal Medicine.

Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults

S. Greenland, R. Kaplan, P. Doshi, 2022, Vaccine.

Control vaccine formulation

T. Jefferson, P. Doshi, A. Rowhani-Farid, 2021, The Lancet.

EMA recommendation on hydroxyethyl starch solutions obscured controversy

P. Doshi, 2018, British Medical Journal.

“Independent” reanalysis of landmark starch solutions trial was published by original authors

P. Doshi, 2017, British Medical Journal.

Incompletely Reported Important Methodological Details and Inaccurate Description of the Formulation That the Control Arms Received in a Gardasil Vaccine Trial

L. Shamseer, F. Bourgeois, T. Jefferson, 2020, mSphere.

Data too important to share: do those who control the data control the message?

P. Doshi, 2016, British Medical Journal.

Influenza vaccination: policy versus evidence

P. Doshi, Peter Doshi, 2006, British medical journal.

Evaluating covid-19 vaccine efficacy and safety in the post-authorisation phase

P. Doshi, C. Prugger, A. Spelsberg, 2021, BMJ.

Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol for a systematic review

Susan Hutfless, Elizabeth A. Stuart, Tianjing Li, 2015, Systematic Reviews.

Correction to: Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol for a systematic review

E. Stuart, E. Mayo-Wilson, S. Vedula, 2018, Alzheimer's Research & Therapy.

Are manufacturers sharing data as promised?

Kay Dickersin, Peter Doshi, Evan Mayo-Wilson, 2015, BMJ : British Medical Journal.

From promises to policies: is big pharma delivering on transparency?

P. Doshi, 2014, BMJ : British Medical Journal.

Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19

J. Lexchin, P. Doshi, J. Graham, 2020, Journal of law and the biosciences.

Covid-19: Do many people have pre-existing immunity?

P. Doshi, 2020, BMJ.

ADHD medications and cardiovascular adverse events in children and adolescents: cross‐national comparison of risk communication in drug labeling

P. Doshi, S. dosReis, J. Sieluk, 2017, Pharmacoepidemiology and drug safety.

Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments

Tom Jefferson, Igho Onakpoya, Peter Doshi, 2014, BMJ : British Medical Journal.

Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology

Florence T. Bourgeois, L. Shamseer, F. Bourgeois, 2020, BMJ Evidence-Based Medicine.

Will covid-19 vaccines save lives? Current trials aren’t designed to tell us

P. Doshi, 2020, BMJ.

Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies

P. Doshi, C. Prugger, A. Spelsberg, 2017, British Medical Journal.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children-a review of unpublished data Protocol information

D. Nunan, C. Del Mar, Matthew J. Thompson, 2010 .

The elusive definition of pandemic influenza.

P. Doshi, 2011, Bulletin of the World Health Organization.

Covid-19 vaccine trial protocols released

P. Doshi, 2020, BMJ.

Crowdfunding investigative journalism at The BMJ

P. Doshi, R. Coombes, 2022, British medical journal.

Covid-19 vaccines and treatments: we must have raw data, now

F. Godlee, K. Abbasi, P. Doshi, 2022, BMJ.

Transparency of COVID-19 vaccine trials: decisions without data

T. Jefferson, P. Doshi, A. Rowhani-Farid, 2021, BMJ Evidence-Based Medicine.

Canada finally opens up data on new drugs and devices

J. Lexchin, P. Doshi, M. Herder, 2019, BMJ.

Neuraminidase inhibitors—the story behind the Cochrane review

Peter Doshi, P. Doshi, 2009, BMJ : British Medical Journal.

Covid-19: Spreading vaccine “misinformation” puts licence at risk, US boards tell physicians

P. Doshi, 2021, BMJ.

The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors

S. Golder, I. Boutron, L. Stewart, 2018, Systematic Reviews.

Covid-19 vaccines: In the rush for regulatory approval, do we need more data?

P. Doshi, 2021, BMJ.

Influenza: marketing vaccine by marketing disease

P. Doshi, 2013, BMJ.

Convicting Zika

P. Doshi, 2016, British Medical Journal.

Antibiotics Approved for Marketing in Populations Specifically Excluded From Premarketing Trials, 1999-2018.

J. Powers, P. Doshi, A. Kuzucan, 2020, Mayo Clinic proceedings.

Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data.

D. Nunan, C. Del Mar, Matthew J. Thompson, 2016, Health technology assessment.

Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events.

E. Mayo-Wilson, S. Vedula, K. Dickersin, 2019, Journal of clinical epidemiology.

When to include clinical study reports and regulatory documents in systematic reviews

S. Golder, I. Boutron, L. Stewart, 2018, BMJ Evidence-Based Medicine.

Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports

C. Del Mar, Matthew J. Thompson, C. Heneghan, 2014, BMJ Open.

YODA and truth seeking in medicine

S. Vedula, Tianjing Li, P. Doshi, 2013, BMJ.

Open data 5 years on: a case series of 12 freedom of information requests for regulatory data to the European Medicines Agency

T. Jefferson, P. Doshi, 2016, Trials.

Informed Consent to Study Purpose in Randomized Clinical Trials of Antibiotics, 1991 Through 2011

J. Powers, D. Morgan, Mark Jones, 2017, JAMA internal medicine.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis

Tom Jefferson, Peter Doshi, Chris Del Mar, 2009, BMJ : British Medical Journal.

Multisystem failure: the story of anti-influenza drugs

T. Jefferson, P. Doshi, 2014, BMJ : British Medical Journal.

Definition and rationale for placebo composition: Cross-sectional analysis of randomized trials and protocols published in high-impact medical journals

P. Doshi, A. Rowhani-Farid, Kyungwan Hong, 2023, Clinical trials.

Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling

J. Powers, P. Doshi, Kyungwan Hong, 2019, Journal of General Internal Medicine.

Did the FDA break its own rules in approving the antibiotic Recarbrio?

P. Doshi, 2023, British medical journal.

The end of the pandemic will not be televised

P. Doshi, David Robertson, 2021, BMJ.

21st century cures: is US medicines bill a colossal mistake?

P. Doshi, 2015, BMJ : British Medical Journal.

For-profit Uses of Real-World Data: What Would Frances Kelsey Do?

P. Doshi, J. Zito, 2016, Medical care.

Neuropsychiatric adverse events and oseltamivir for prophylaxis.

T. Jefferson, P. Doshi, R. Hama, 2012, Drug safety.

Another question for GSK

T. Jefferson, P. Doshi, 2010, BMJ : British Medical Journal.

The evidence base for new drugs

T. Jefferson, P. Doshi, P. Doshi, 2015, BMJ : British Medical Journal.

Calibrated response to emerging infections

Peter Doshi, P. Doshi, 2009, BMJ : British Medical Journal.

How should we plan for pandemics

P. Doshi, 2009 .

Commentary on Cochrane review of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.

C. Del Mar, C. Heneghan, T. Jefferson, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Influenza vaccination of health care workers

J. Lexchin, T. Jefferson, P. Doshi, 2013, Canadian Medical Association Journal.

Time for change, WHO

T. Jefferson, P. Doshi, 2010, British medical journal.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults.

V Demicheli, T. Jefferson, V. Demicheli, 2011, The Cochrane database of systematic reviews.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.

D. Nunan, C. Del Mar, Matthew J. Thompson, 2014, The Cochrane database of systematic reviews.

Findings of an Observational Study of Neuraminidase Inhibitors Highly Sensitive to Decision to Exclude 1652 Treated Patients.

C. Del Mar, P. Doshi, Mark Jones, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Sources of bias in observational studies of covid-19 vaccine effectiveness.

P. Doshi, Mark Jones, K. Fung, 2023, Journal of evaluation in clinical practice.

Availability of study protocols for randomized trials published in high-impact medical journals: A cross-sectional analysis

P. Doshi, O. Spence, Kyungwan Hong, 2020, Clinical trials.

Influenza vaccination of health care workers

Nicholas S. Kelley, M. Osterholm, J. Lexchin, 2013, Canadian Medical Association Journal.

The evidence base for new drugs

T. Jefferson, P. Doshi, 2015, BMJ : British Medical Journal.

Restoring invisible and abandoned trials: a call for people to publish the findings

S. Vedula, T. Jefferson, P. Doshi, 2013, BMJ.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults.

T. Jefferson, V. Demicheli, D. Nunan, 2006, The Cochrane database of systematic reviews.

No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility

P. Doshi, 2015, BMJ : British Medical Journal.

Are US flu death figures more PR than science?

P. Doshi, 2005, BMJ : British Medical Journal.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults.

D. Nunan, Matthew J. Thompson, C. Heneghan, 2006, The Cochrane database of systematic reviews.

Do many people have pre-existing immunity to covid-19?

P. Doshi, 2020, BMJ.

Clinical trials: Tamiflu reviewers respond to critics

T. Jefferson, P. Doshi, 2014, Nature.

Patient consent to publication and data sharing in industry and NIH-funded clinical trials

P. Doshi, O. Spence, Richie Onwuchekwa Uba, 2018, Trials.

Contradictory findings on efficacy of neuraminidase inhibitors not cited.

C. Heneghan, T. Jefferson, P. Doshi, 2020, The Journal of infectious diseases.

Influenza vaccines: time for a rethink.

P. Doshi, 2013, JAMA internal medicine.